A new eye-focused biotech is out of stealth, with plans to barrel toward PhII studies

A new biotech emerged from stealth and joined the Massachusetts biotech scene this morning, announcing its launch with a Series A for $10.5 million.

Aramis Biosciences, founded back in 2018, had its financing round led by Cambridge-based investors Safar Partners, alongside a strategic investment from an unnamed ophthalmic pharmaceutical company.